KILITCH DRUGS (INDIA) LTD. - 524500 - Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Bhavin Mukund Mehta KILITCH DRUGS (INDIA) LTD. - 524500 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Mukund Mehta KILITCH DRUGS (INDIA) LTD. - 524500 - Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), we inform you that Ms. Princy Asati, Company Secretary & Compliance Officer of the Company has resigned with effect from close of working hours of April 15, 2022. The company has accepted his resignation and relieved him from his responsibility with effect from close of business hours on April 15, 2022. Her successor shall be appointed shortly and the same shall be intimated to Stock Exchange(s). Kindly take the same on your records. KILITCH DRUGS (INDIA) LTD. - 524500 - Non Applicability Of SEBI Circular (SEBI/HO/DDHS/CIR/P/2018/144) Dated 26 November 2018
In connection with the above subject, we hereby confirm that our Company does not fall under the criteria for Large Corporate (LC) as per the applicability criteria mentioned in SEBI Circular (SEBI/HO/DDHS/CIR/P/2018/144) dated 26 November 2018. KILITCH DRUGS (INDIA) LTD. - 524500 - Certificate Under Regulation 40(9) Of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015
With reference to Regulation 40(9) of Securities Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2015, please find attached herewith the certificate dated 11th April, 2022 received from M/s. Deep Shukla & Associates, Practicing Company Secretaries for the year ended 31st March 2022. Kindly take the same on your records. KILITCH DRUGS (INDIA) LTD. - 524500 - Disclosures under Reg. 10(5) in respect of acquisition under Reg. 10(1)(a) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 10(5) in respect of acquisition under Regulation 10(1)(a) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Bhavin Mehta KILITCH DRUGS (INDIA) LTD. - 524500 - Disclosures Under Regulation 7(2)(B) Of Securities And Exchange Board Of India(Prohibition Of Insider Trading) Regulations 2015.
In terms of Regulation 7(2)(b) of SEBI (Prohibition of Insider Trading) Regulations, 2015, enclosed please find disclosures received from Mr.Mukund Mehta , one of the insider belonging to promoters group, in Form ''C'' pursuant to Regulation 7(2)(a) of SEBI (Prohibition of Insider Trading) Regulations, 2015, regarding transmission of 1111768 equity shares held in the name of Late Mrs. Neeta Mehta on 11-04-2022. KILITCH DRUGS (INDIA) LTD. - 524500 - Disclosures under Reg. 29(1) / 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(1) / 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Mukund Mehta KILITCH DRUGS (INDIA) LTD. - 524500 - Reply To The Clarification Sought On Price Movement Of The Shares Of The Company.
With reference to clarification sought by your good office, we wish to inform you that the Company has made all the necessary disclosures pursuant to regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 and has not withheld any material information/event that in our opinion would have bearing on the price behavior of the scrip. The Company shall continue to make applicable disclosures, within the stipulated time. Therefore, the movement in the share price of the company is purely due to market conditions and absolutely market driven and the management of the company is in no way connected with any such movement in price. You are requested to take the same on your record. KILITCH DRUGS (INDIA) LTD. - 524500 - Clarification sought from Kilitch Drugs India Ltd
The Exchange has sought clarification from Kilitch Drugs India Ltd on April 8, 2022 with reference to significant movement in price, in order to ensure that investors have latest relevant information about the company and to inform the market so that the interest of the investors is safeguarded.The reply is awaited.